When would a New Drug Application (NDA) be submitted?

When would a New Drug Application (NDA) be submitted?

• A. after marketing
• B. after Phase I
• C. once all phases demonstrate safety and effectiveness
• D. before Phase III

Answer: (C)

Submitting a New Drug Application is done once enough clinical data have shown the drug is both safe and effective for its intended use. In practice, this means the sponsor files after the pivotal clinical program has completed—typically after Phase 3 trials, when large-scale evidence supports efficacy and an acceptable safety profile across the studied population. The NDA bundles all preclinical and clinical data, plus proposed labeling and manufacturing details, so the FDA can evaluate whether the benefits outweigh the risks and whether the product can be marketed with appropriate controls. Why the other timing options don’t fit: marketing the drug before the NDA would be illegal without approval; submitting after Phase I would be premature because safety and efficacy are not yet established; submitting before Phase III would lack the comprehensive confirmatory data that Phase 3 provides.

Submitting a New Drug Application is done once enough clinical data have shown the drug is both safe and effective for its intended use. In practice, this means the sponsor files after the pivotal clinical program has completed—typically after Phase 3 trials, when large-scale evidence supports efficacy and an acceptable safety profile across the studied population. The NDA bundles all preclinical and clinical data, plus proposed labeling and manufacturing details, so the FDA can evaluate whether the benefits outweigh the risks and whether the product can be marketed with appropriate controls.

Why the other timing options don’t fit: marketing the drug before the NDA would be illegal without approval; submitting after Phase I would be premature because safety and efficacy are not yet established; submitting before Phase III would lack the comprehensive confirmatory data that Phase 3 provides.